Shilpa Medicare Ltd

Shilpa Medicare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a modest day gain of 0.41%, the company’s technical indicators present a complex picture, with bullish signals on some fronts and bearish or neutral cues on others, prompting a downgrade in its Mojo Grade from Hold to Sell as of 27 Apr 2026.

Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 2 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 April 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shilpa Medicare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced outlook for investors as the stock price advances to ₹388.00, up 3.69% on 6 Apr 2026.

Shilpa Medicare Ltd has seen its investment rating upgraded from Sell to Hold as of 2 April 2026, reflecting notable improvements across technical indicators, valuation metrics, and financial performance. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that have driven this change, providing investors with a detailed understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector.

The Sensex advanced 2.49% on 1 Apr 2026, yet Shilpa Medicare Ltd outpaced the broader market with a 7.84% gain, reaching an intraday high of Rs 376.2. This 5.77-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.07% rise signals a distinctly stock-specific surge rather than a mere market tailwind.

Shilpa Medicare Ltd commenced trading on 1 April 2026 with a notable gap up, opening 5.06% higher than its previous close, reflecting a strong start and positive market sentiment despite a 'Sell' rating by MarketsMOJO. The stock demonstrated robust intraday momentum, touching a high of Rs 366.3, supported by favourable technical indicators and outperforming the broader Sensex index.

Shilpa Medicare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish trend to a sideways stance. Despite a 2.01% gain on 27 Mar 2026, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes, reflecting cautious optimism amid sector headwinds.

The Sensex declined by 1.34% on 24 Mar 2026, while Shilpa Medicare Ltd surged 8.07%, outperforming its Pharmaceuticals & Biotechnology sector by 6.47 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market environment.

Shilpa Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shilpa Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Shilpa Medicare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 February 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shilpa Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Shilpa Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 February 2026, providing investors with the latest insights into its performance and outlook.

Shilpa Medicare Ltd recorded a robust intraday performance on 09 Feb 2026, surging to a day’s high of Rs 359.95, marking a significant 7.33% gain. The pharmaceutical and biotechnology company outpaced its sector and the broader market, reflecting heightened trading activity and volatility.

Shilpa Medicare Ltd commenced trading today with a significant gap up, opening 14.47% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start was accompanied by heightened volatility and outperformance relative to both its sector and the broader market indices.